Plos iconPlosOct 1, 2026 ~1 min source read

Targeting of conserved spike epitopes enables broad antibody neutralisation of diverse bat sarbecoviruses

by Ayush Upadhyay, Jeffrey Seow, Yilmaz Alguel, Joseph Newman, Nazia Thakur, Abigail L. Here we study the neutralising epitopes on WIV-1 Spike of three mAbs that confer broad sarbecovirus and SARS-CoV-2 variant neutralisation, including XEC, JN.1, and XFG.

Targeting of conserved spike epitopes enables broad antibody neutralisation of diverse bat sarbecoviruses
Read original More from Plos

Share this story

Send the public story page.

Useful takeaways from this story.

by Ayush Upadhyay, Jeffrey Seow, Yilmaz Alguel, Joseph Newman, Nazia Thakur, Abigail L.

Here we study the neutralising epitopes on WIV-1 Spike of three mAbs that confer broad sarbecovirus and SARS-CoV-2 variant neutralisation, including XEC, JN.1, and XFG.

mAb V1WT_06 binds a highly conserved RBD site V epitope that is mediated by the heavy chain alone.

Building the complete brief

The page is ready to read now. The fuller skim-friendly version will appear here automatically.

The useful part

by Ayush Upadhyay, Jeffrey Seow, Yilmaz Alguel, Joseph Newman, Nazia Thakur, Abigail L. Here we study the neutralising epitopes on WIV-1 Spike of three mAbs that confer broad sarbecovirus and SARS-CoV-2 variant neutralisation, including XEC, JN.1, and XFG. mAb V1WT_06 binds a highly conserved RBD site V epitope that is mediated by the heavy chain alone.

How it works

  • We show that neutralisation by these mAbs is maintained when virus entry is via Japanese horseshoe bat and Halcyon horseshoe bat ACE2s.
  • V1WT_06 contact residues are highly conserved in circulating viruses suggesting that the epitope is evolutionarily and functionally constrained.
  • These mAbs are ideal candidates for therapeutic antibody development and inform the rational design of pan-betacoronavirus vaccines.

Details worth keeping

Orton, Dalan Bailey, Peter Cherepanov, Katie J.

Keep reading in the app

Open the app view to save this story, compare related coverage, and continue from the same source.

Open in app